Hubert Josien
Overview
Explore the profile of Hubert Josien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandramohan A, Josien H, Yuen T, Duggal R, Spiegelberg D, Yan L, et al.
Nat Commun
. 2025 Feb;
16(1):1617.
PMID: 39948100
No abstract available.
2.
Fawaz M, Sun C, Feng Y, Qirjollari A, Josien H, DeBord D, et al.
J Am Soc Mass Spectrom
. 2024 Jul;
35(11):2596-2607.
PMID: 38992936
Cyclic peptides are an important class of molecules that gained significant attention in the field of drug discovery due to their unique pharmacological characteristics and enhanced proteolytic stability. Yet, gastrointestinal...
3.
Chandramohan A, Josien H, Yuen T, Duggal R, Spiegelberg D, Yan L, et al.
Nat Commun
. 2024 Jan;
15(1):489.
PMID: 38216578
Although stapled α-helical peptides can address challenging targets, their advancement is impeded by poor understandings for making them cell permeable while avoiding off-target toxicities. By synthesizing >350 molecules, we present...
4.
Kasper S, Otten S, Squadroni B, Orr-Terry C, Kuang Y, Mussallem L, et al.
Bioeng Transl Med
. 2023 Sep;
8(5):e10542.
PMID: 37693049
Cyclic peptides are poised to target historically difficult to drug intracellular protein-protein interactions, however, their general cell impermeability poses a challenge for characterizing function. Recent advances in microfluidics have enabled...
5.
Johns D, Campeau L, Banka P, Bautmans A, Bueters T, Bianchi E, et al.
Circulation
. 2023 May;
148(2):144-158.
PMID: 37125593
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2...
6.
Shang J, Tschirret-Guth R, Cancilla M, Samuel K, Chen Q, Chobanian H, et al.
Chem Res Toxicol
. 2019 Oct;
33(1):191-201.
PMID: 31566356
MK-8666, a selective GPR40 agonist developed for the treatment of type 2 diabetes mellitus, was discontinued in phase I clinical trials due to liver safety concerns. To address whether chemically...
7.
Pio B, Chobanian H, Guo Y, Josien H, Hagmann W, Miller M, et al.
Bioorg Med Chem Lett
. 2019 May;
29(14):1842-1848.
PMID: 31109791
GPR40 (FFAR1 or FFA1) is a G protein-coupled receptor, primarily expressed in pancreatic islet β-cells and intestinal enteroendocrine cells. When activated by fatty acids, GPR40 elicits increased insulin secretion from...
8.
Lu J, Byrne N, Wang J, Bricogne G, Brown F, Chobanian H, et al.
Nat Struct Mol Biol
. 2017 Jun;
24(7):570-577.
PMID: 28581512
Clinical studies indicate that partial agonists of the G-protein-coupled, free fatty acid receptor 1 GPR40 enhance glucose-dependent insulin secretion and represent a potential mechanism for the treatment of type 2...
9.
Plummer C, Clements M, Chen H, Rajagopalan M, Josien H, Hagmann W, et al.
ACS Med Chem Lett
. 2017 Feb;
8(2):221-226.
PMID: 28197316
GPR40 is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40...
10.
Neelamkavil S, Agrawal S, Bara T, Bennett C, Bhat S, Biswas D, et al.
ACS Med Chem Lett
. 2016 Jan;
7(1):111-6.
PMID: 26819676
We have been focused on identifying a structurally different next generation inhibitor to MK-5172 (our Ns3/4a protease inhibitor currently under regulatory review), which would achieve superior pangenotypic activity with acceptable...